A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse cardiovascular and venous thromboembolic events compared with those treated ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of ...

Abatacept (Orencia) is prescribed for psoriatic arthritis and other autoimmune conditions. Interaction result: Treatment with Stelara and abatacept can increase the risk of infection from either ...

“Psoriatic arthritis is a complex disease involving both the skin and the joints with a heterogeneous range of clinical manifestations, and it requires treatment options with different ...

Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria. Review of the applications is expected to by completed in Q4 2025, ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Bimekizumab – an IL-17A and IL-17F inhibitor – outdid both placebo and IL-12/IL-23 blocker Stelara (ustekinumab ... additional data in psoriasis, psoriatic arthritis and ankylosing spondylitis ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...